Grant: Project Grant
University of Ottawa
$895,050.00
Dilated cardiomyopathy: Going postnatal on the E2F pathway by tempering E2F6 activity
EF 2021-22
Résumé
As some people age the heart becomes less efficient in pumping blood out of the ventricles
and fills with blood to dilate like a balloon. This defect may also be observed and accelerated
if the heart is stressed or is subjected to cancer therapy such as seen in patients on
chemotherapeutic agents. In fact a large number of cancer patients die from heart disease
known as dilated cardiomyopathy or the balloon heart induced by certain cancer drugs. In
addition, susceptibility to chemo treatment and heart disease is sex related. We have
discovered a new pathway that can control the genes involved in causing the dilated heart
syndrome. In fact we have found a gene therapy (its like a drug) that can prevent the damage
that chemotherapeutic drugs induce in the cells that make up the heart muscle. This gene
therapy can also help heart cells survive better in response to stress. These studies were
conducted in cells isolated `from the mouse heart. We propose to use the gene therapy in
animal models of stress and drug induced dilated heart disease to examine its use as a
treatment to prevent the balloon heart syndrome. Old age, stress and drugs used to treat
cancer can lead to dilated heart disease and there is no treatment. It is notable that in about
35% of patients exhibiting dilated heart disease , the cause remains unknown. For the first
time, our results identify that the deregulation of the E2F pathway leads to this disease by
influencing energy utilization and receiving/collating essential information in the heart cells.
Our data points to new mechanisms that lead to dilated hearts. Here we propose studies to
further interrogate these new mechanisms that will pave the way to potentially treating this
fatal disease through discovery science as detailed in our research program
Programme
Project Grant
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
453163
Name
Tuana Balwant S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Cardiovascular System - B: Heart and Circulation
Projecttitle
Dilated cardiomyopathy: Going postnatal on the E2F pathway by tempering E2F6 activity
Programtype2
Operating Grants
Orgnameinp2
University of Ottawa
Cihramount2
$895,050
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Cardiac Remodeling; Dilated Heart Disease; Gene Expression; Gene Therapy; Signaling; Transcription
Abstract
As some people age the heart becomes less efficient in pumping blood out of the ventricles
and fills with blood to dilate like a balloon. This defect may also be observed and accelerated
if the heart is stressed or is subjected to cancer therapy such as seen in patients on
chemotherapeutic agents. In fact a large number of cancer patients die from heart disease
known as dilated cardiomyopathy or the balloon heart induced by certain cancer drugs. In
addition, susceptibility to chemo treatment and heart disease is sex related. We have
discovered a new pathway that can control the genes involved in causing the dilated heart
syndrome. In fact we have found a gene therapy (its like a drug) that can prevent the damage
that chemotherapeutic drugs induce in the cells that make up the heart muscle. This gene
therapy can also help heart cells survive better in response to stress. These studies were
conducted in cells isolated `from the mouse heart. We propose to use the gene therapy in
animal models of stress and drug induced dilated heart disease to examine its use as a
treatment to prevent the balloon heart syndrome. Old age, stress and drugs used to treat
cancer can lead to dilated heart disease and there is no treatment. It is notable that in about
35% of patients exhibiting dilated heart disease , the cause remains unknown. For the first
time, our results identify that the deregulation of the E2F pathway leads to this disease by
influencing energy utilization and receiving/collating essential information in the heart cells.
Our data points to new mechanisms that lead to dilated hearts. Here we propose studies to
further interrogate these new mechanisms that will pave the way to potentially treating this
fatal disease through discovery science as detailed in our research program
Competitiondate
202109
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Tuana, Balwant S
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $895,050~ $0~